Diagnostic accuracy of point of care faecal immunochemical testing using a portable high-speed quantitative analyser for diagnosis in 2-week wait patients.


Journal

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
ISSN: 1463-1318
Titre abrégé: Colorectal Dis
Pays: England
ID NLM: 100883611

Informations de publication

Date de publication:
Sep 2021
Historique:
revised: 26 05 2021
received: 12 02 2021
accepted: 16 06 2021
pubmed: 23 6 2021
medline: 5 10 2021
entrez: 22 6 2021
Statut: ppublish

Résumé

Laboratory-based faecal immunochemical testing (FIT) is the gold standard for detecting the presence of blood in the stool. The aim was to perform a diagnostic accuracy study to confirm if a point of care (POC) analyser for FIT could be safely used as an adjunct in the triage and management of 2-week wait (TWW) colorectal patients. The Point of Care Faecal Immunochemical Testing (POC FIT) prospective observational cohort study was designed for TWW patients at a regional referral centre. Between July 2019 and March 2020, patients were invited to perform and bring a FIT sample to clinic. FIT was completed within the clinic appointment using a POC quantitative analyser that has a 2-min processing time (QuikRead go®). Patients and clinicians were blinded to results within the clinic appointment. The results were compared with subsequent diagnostic outcomes. Faecal haemoglobin of <10 µg haemoglobin/g of faeces was considered a negative result. Sensitivities for colorectal cancer (CRC) and combined serious bowel disease (SBD) were calculated using this pre-determined cut-off. A total of 553 patients were included for analytical comparison with diagnostic outcomes. There were 14 (2.5%) patients with CRC and 52 (9.4%) with SBD. The sensitivities for CRC and SBD were 92.9% (95% CI 68.5%-98.7%) and 76.9% (95% CI 63.9%-86.3%) respectively. 379 (68.5%) patients had a negative FIT result (negative predictive value for CRC was 99.7%). This POC FIT device is a useful adjunct to better manage TWW patients. The high observed sensitivity for CRC offers opportunities, within a single consultation, for improved triage and rationalization of investigation for those with bowel symptoms.

Identifiants

pubmed: 34157205
doi: 10.1111/codi.15780
doi:

Substances chimiques

Hemoglobins 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2376-2386

Subventions

Organisme : GUTSfbc

Informations de copyright

© 2021 The Authors. Colorectal Disease published by John Wiley & Sons Ltd on behalf of Association of Coloproctology of Great Britain and Ireland.

Références

Arasaradnam RP, Bhala N, Evans C, Greenaway J, Logan R, Penman I, et al. Faecal immunochemical testing in the COVID-19 era: balancing risk and costs. Lancet Gastroenterol Hepatol. 2020;5(8):717-9. https://doi.org/10.1016/S2468-1253(20)30185-0
D'Souza N, Georgiou Delisle T, Chen M, Benton S, Abulafi M. Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway: a diagnostic accuracy study. Gut. 2021;70(6):1130-8.
Högberg C, Gunnarsson U, Jansson S, Thulesius H, Cronberg O, Lilja M. Diagnosing colorectal cancer in primary care: cohort study in Sweden of qualitative faecal immunochemical tests, haemoglobin levels, and platelet counts. Br J Gen Pract. 2020;70(701):E843-51.
McSorley ST, Digby J, Clyde D, Cruickshank N, Burton P, Barker L, et al. Yield of colorectal cancer at colonoscopy according to faecal haemoglobin concentration in symptomatic patients referred from primary care. Colorectal Dis. 2020;22:1-7. https://doi.org/10.1111/codi.15405
Chapman C, Thomas C, Morling J, Tangri A, Oliver S, Simpson JA, et al. Early clinical outcomes of a rapid colorectal cancer diagnosis pathway using faecal immunochemical testing in Nottingham. Colorectal Dis. 2020;22:679-88.
Vieito NP, Zarraquiños S, Cubiella J. High-risk symptoms and quantitative faecal immunochemical test accuracy: systematic review and meta-analysis. World J Gastroenterol. 2019;25(19):2383-401.
National Institute for Health and Care Excellence. Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care Diagnostics guidance. NICE [Internet]. 2017. Available from: https://www.nice.org.uk/guidance/dg30/resources/quantitative-faecal-immunochemical-tests-to-guide-referral-for-colorectal-cancer-in-primary-care-pdf-1053744003781. Accessed 15 January 2021.
D'Souza N, Hicks G, Benton SC, Abulafi M. The diagnostic accuracy of the faecal immunochemical test for colorectal cancer in risk-stratified symptomatic patients. Ann R Coll Surg Engl. 2020;102(3):174-9.
Bailey JA, Khawaja A, Andrews H, Weller J, Chapman C, Morling JR, et al. GP access to FIT increases the proportion of colorectal cancers detected on urgent pathways in symptomatic patients in Nottingham. Surgeon. 2021;19:93-102.
Huddy JR, Ni M, Misra S, Mavroveli S, Barlow J, Hanna GB. Development of the Point-of-Care Key Evidence Tool (POCKET): a checklist for multi-dimensional evidence generation in point-of-care tests. Clin Chem Lab Med. 2019;57(6):845-55.
Huddy JR, Ni MZ, Markar SR, Hanna GB. Point-of-care testing in the diagnosis of gastrointestinal cancers: current technology and future directions. World J Gastroenterol. 2015;21(14):4111-20.
Nicholson B, Thompson M, Price CP, Heneghan C, Pluddemann A. Point-of-care faecal occult blood testing. 2014;(1):85-94. Available from: http://www.oxford.dec.nihr.ac.uk/reports/horizon-scanning/point-of-care-faecal-occult-blood-testing. Accessed 15 January 2021.
Nicholson BD, Price CP, Heneghan C, Plüddemann A, Thompson M. Home-use faecal immunochemical testing: primary care diagnostic technology update. Br J Gen Pract. 2015;65:156-8.
O'Driscoll S, Carroll M, Maclean W, Piggott C, Jourdan I, Benton SC. Assessment of the analytical performance of point-of-care faecal immunochemical tests for haemoglobin. Ann Clin Biochem. 2021;58:181-9.
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Radiology. 2015;277(3):826-32.
Brown LF, Fraser CG. Effect of delay in sampling on haemoglobin determined by faecal immunochemical tests. Ann Clin Biochem. 2008;45(6):604-5.
Martín-López JE, Beltrán-Calvo C, Rodríguez-López R, Molina-López T. Comparison of the accuracy of CT colonography and colonoscopy in the diagnosis of colorectal cancer. Colorectal Dis. 2014;16(3):82-90.
Fraser CG, Allison JE, Young GP, Halloran SP, Seaman H. A standard for Faecal Immunochemical TesTs for Haemoglobin Evaluation Reporting (FITTER). Ann Clin Biochem. 2014;51(2):301-2.
Westwood M, Corro Ramos I, Lang S, Luyendijk M, Zaim R, Stirk L, et al. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2017;21(33):1-234.
Šimundić AM. Measures of diagnostic accuracy: basic definitions. Ejifcc. 2009;19(4):203-11.
CLSI. User protocol for evaluation of qualitative test performance; approved guideline-second edition. CLSI document EP12-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837-45.
Rutter MD, East J, Rees CJ, Cripps N, Docherty J, Dolwani S, et al. British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines. Gut. 2020;69(2):201-23.
Tsapournas G, Hellström PM, Cao Y, Olsson LI. Diagnostic accuracy of a quantitative faecal immunochemical test vs. symptoms suspected for colorectal cancer in patients referred for colonoscopy. Scand J Gastroenterol. 2020;55(2):184-92. https://doi.org/10.1080/00365521.2019.1708965
Gies A, Cuk K, Schrotz-King P, Brenner H. Direct comparison of diagnostic performance of 9 quantitative fecal immunochemical tests for colorectal cancer screening. Gastroenterology. 2018;154(1):93-104. https://doi.org/10.1053/j.gastro.2017.09.018
NHSE. Clinical guide for triaging patients with lower GI symptoms. NHSE Guid Approv Ref 001559. 2020; (June 2020).
Maclean W, Limb C, Mackenzie P, Whyte MB, Benton SC, Rockall T, et al. Adoption of faecal immunochemical testing for 2-week-wait colorectal patients during the COVID-19 pandemic: an observational cohort study reporting a new service at a regional centre. Colorectal Dis. 2020;23:1622-1629. https://doi.org/10.1111/codi.15408
Public Health England. Routes to diagnosis 2015 update: colorectal cancer. 2015;p. 1-5. www.ncin.org.uk/view?rid=3147. Accessed May 2021.
Maclean W, Singh R, Mackenzie P, White D, Benton S, Stebbing J, et al. The two-week rule colorectal cancer pathway: an update on recent practice, the unsustainable burden on diagnostics and the role of faecal immunochemical testing. Ann R Coll Surg Engl. 2020;102:308-11.
Mowat C, Digby J, Strachan JA, McCann R, Hall C, Heather D, et al. Impact of introducing a faecal immunochemical test (FIT) for haemoglobin into primary care on the outcome of patients with new bowel symptoms: a prospective cohort study. BMJ Open Gastroenterol. 2019;6(1):e000293.
Khan AA, Klimovskij M, Harshen R. Accuracy of faecal immunochemical testing in patients with symptomatic colorectal cancer. BJS Open. 2020;4(6):1180-8.
Grainger J, Skaife P. PWE-338 digital rectal examination: a discriminatory test in the diagnosis of colorectal cancer. Gut. 2015;64(Suppl 1):A358.
Widlak MM, Thomas CL, Thomas MG, Tomkins C, Smith S, O'Connell N, et al. Diagnostic accuracy of faecal biomarkers in detecting colorectal cancer and adenoma in symptomatic patients. Aliment Pharmacol Ther. 2017;45(2):354-63.
Mowat C, Digby J, Strachan JA, McCann RK, Carey FA, Fraser CG, et al. Faecal haemoglobin concentration thresholds for reassurance and urgent investigation for colorectal cancer based on a faecal immunochemical test (FIT) in symptomatic patients in primary care. Ann Clin Biochem Int J Lab Med. 2021;58:211-9.
Yang C, Sriranjan V, Abou-Setta AM, Poluha W, Walker JR, Singh H. Anxiety associated with colonoscopy and flexible sigmoidoscopy: a systematic review. Am J Gastroenterol. 2018;113:1810-8. https://doi.org/10.1038/s41395-018-0398-8
Burr NE, Derbyshire E, Taylor J, Whalley S, Subramanian V, Finan PJ, et al. Variation in post-colonoscopy colorectal cancer across colonoscopy providers in English National Health Service: population based cohort study. BMJ. 2019;367:l6090.

Auteurs

William Maclean (W)

General Surgery at Royal Surrey NHS Foundation Trust, Guildford, UK.

Paul Mackenzie (P)

General Surgery at Royal Surrey NHS Foundation Trust, Guildford, UK.

Chris Limb (C)

General Surgery at Royal Surrey NHS Foundation Trust, Guildford, UK.

Zahida Zahoor (Z)

Bowel Cancer Screening Hub at Royal Surrey NHS Foundation Trust, Guildford, UK.

Martin B Whyte (MB)

Metabolic Medicine at University of Surrey, Guildford, UK.

Timothy Rockall (T)

General Surgery at Royal Surrey NHS Foundation Trust, Guildford, UK.

Sally C Benton (SC)

Bowel Cancer Screening Hub at Royal Surrey NHS Foundation Trust, Guildford, UK.

Iain Jourdan (I)

General Surgery at Royal Surrey NHS Foundation Trust, Guildford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH